Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 12/2021

01-12-2021 | Hepatitis B | Original Article

Advanced Liver Fibrosis Is Associated with Necroinflammatory Grade but Not Hepatic Steatosis in Chronic Hepatitis B Patients

Authors: Yi-Cheng Chen, Chao-Wei Hsu, Wen-Juei Jeng, Chun-Yen Lin

Published in: Digestive Diseases and Sciences | Issue 12/2021

Login to get access

Abstract

Background and Aims

Patients with chronic hepatitis B (CHB) are at an increased risk of disease progression. The influence of hepatic steatosis (HS) to liver fibrosis was controversial. We aim to investigate the association between HS and liver fibrosis and explore the predicting factors for advanced fibrosis.

Methods

CHB patients undergoing liver biopsy with complete assessments of HS, necroinflammation grade [histological activity index (HAI) score], and fibrosis stage were retrospectively recruited. Logistic regression analysis was performed to determine the factors associated with advanced liver fibrosis.

Results

In this cohort of 672 patients, 342 (50.9%) had HS and 267 (39.4%) were of advanced liver fibrosis. Age [odds ratio (OR) 1.026, 95% confidence interval (CI) 1.007–1.046, p = 0.008], body mass index (BMI, OR 1.091, 95% CI 1.026–1.159, p = 0.005), genotype (C vs. B) (OR 2.790, 95% CI 1.847–4.214, p < 0.001), platelet (OR 0.986, 95% CI 0.982–0.991, p < 0.001), and HAI score (OR 1.197, 95% CI 1.114–1.285, p < 0.001) were independent factors for advanced liver fibrosis in multivariate logistic regression analysis. HAI score was also a significantly associated factor for significant liver fibrosis in non-cirrhotic subpopulation (OR 1.578, 95% CI 1.375–1.810, p < 0.001). HS was not related to advanced/significant liver fibrosis in overall/non-cirrhotic population (p > 0.05).

Conclusions

Significant or advanced liver fibrosis is associated with grade of necroinflammation but not with HS in CHB patients.
Appendix
Available only for authorised users
Literature
1.
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–1555PubMedCrossRef
2.
Liaw YF, Chu CM. Hepatitis B virus infection. Lancet (London, England). 2009;373:582–592CrossRef
3.
Sarin SK, Kumar M, Lau GK et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1–98PubMedCrossRef
4.
Lee MH, Yang HI, Liu J et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology 2013;58:546–554PubMedCrossRef
5.
Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328–357PubMedCrossRef
6.
Fan JG, Chitturi S. Hepatitis B and fatty liver: causal or coincidental? J Gastroenterol Hepatol 2008;23:679–681PubMedCrossRef
7.
Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol 2011;26:1361–1367PubMed
8.
Wong GL, Wong VW, Choi PC et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009;58:111–117PubMedCrossRef
9.
Wong GL, Chan HL, Yu Z et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B–a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther 2014;39:883–893PubMedCrossRef
10.
Hui RWH, Seto WK, Cheung KS et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study. J Viral Hepat 2018;25:97–104PubMedCrossRef
11.
Seto WK, Hui RWH, Mak LY et al. Association between hepatic steatosis, measured by controlled attenuation parameter, and fibrosis burden in chronic hepatitis B. Clin Gastroenterol Hepatol 2018;16:e572
12.
Wong SW, Chan WK, Mohamed R. Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B. J Viral Hepat. 2020;12:1297–1305
13.
Tsochatzis E, Papatheodoridis GV, Manesis EK, Kafiri G, Tiniakos DG, Archimandritis AJ. Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008;27:80–89PubMedCrossRef
14.
Yun JW, Cho YK, Park JH et al. Hepatic steatosis and fibrosis in young men with treatment-naive chronic hepatitis B. Liver Int 2009;29:878–883PubMedCrossRef
15.
Charatcharoenwitthaya P, Pongpaibul A, Kaosombatwattana U et al. The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response. Liver Int 2017;37:542–551PubMedCrossRef
16.
Lin CF, Chang YH, Chien SC, Lin YH, Yeh HY. Epidemiology of dyslipidemia in the Asia Pacific Region. Int J Gerontol 2018;12:2–6CrossRef
17.
Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–1325PubMedCrossRef
18.
Hamidi AA, Oncul A, Ozguven BY et al. Diagnostic accuracy of different noninvasive scores for detecting advanced fibrosis in chronic hepatitis B. Eur J Gastroenterol Hepatol 2019;31:1439–1443PubMedCrossRef
19.
Udompap P, Sukonrut K, Suvannarerg V, Pongpaibul A, Charatcharoenwitthaya P. Prospective comparison of transient elastography, point shear wave elastography, APRI and FIB-4 for staging liver fibrosis in chronic viral hepatitis. J Viral Hepat 2020;27:437–448PubMedCrossRef
20.
Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–699CrossRef
21.
Dong XQ, Wu Z, Zhao H, Wang GQ. China Hep BRFARG Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in Chinese hepatitis B patients. J Viral Hepat 2019;26:297–307PubMedCrossRef
22.
Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012;32:3–13PubMedCrossRef
23.
Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–1321PubMedCrossRef
24.
Bedossa P, Poitou C, Veyrie N et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56:1751–1759PubMedCrossRef
25.
Wu YL, Peng XE, Zhu YB, Yan XL, Chen WN, Lin X. Hepatitis B virus X protein induces hepatic steatosis by enhancing the expression of liver fatty acid binding protein. J Virol 2016;90:1729–1740PubMedPubMedCentralCrossRef
26.
Kim KH, Shin HJ, Kim K et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology 2007;132:1955–1967PubMedCrossRef
27.
Oehler N, Volz T, Bhadra OD et al. Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism. Hepatology 2014;60:1483–1493PubMedCrossRef
28.
Geier A. Hepatitis B virus: the “metabolovirus” highjacks cholesterol and bile acid metabolism. Hepatology 2014;60:1458–1460PubMedCrossRef
29.
Minakari M, Molaei M, Shalmani HM et al. Liver steatosis in patients with chronic hepatitis B infection: host and viral risk factors. Eur J Gastroenterol Hepatol. 2009;21:512–516PubMedCrossRef
30.
31.
Tsochatzis E, Papatheodoridis GV, Manesis EK, Chrysanthos N, Kafiri G, Archimandritis AJ. Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Dig Liver Dis 2007;39:936–942PubMedCrossRef
32.
Thomopoulos KC, Arvaniti V, Tsamantas AC et al. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol 2006;18:233–237PubMedCrossRef
33.
Lanthier N, Horsmans Y, Leclercq IA. The metabolic syndrome: how it may influence hepatic stellate cell activation and hepatic fibrosis. Curr Opin Clin Nutr Metab Care. 2009;12:404–411PubMedCrossRef
34.
Katsiki N, Perez-Martinez P, Anagnostis P, Mikhailidis DP, Karagiannis A. Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome? Curr Vasc Pharmacol 2018;16:219–227PubMedCrossRef
35.
Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525–540PubMedCrossRef
36.
Shen F, Mi YQ, Xu L et al. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis. Aliment Pharmacol Ther 2019;50:93–102PubMedCrossRef
37.
Shi JP, Fan JG, Wu R et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol 2008;23:1419–1425PubMedCrossRef
38.
Asselah T, Boyer N, Guimont MC et al. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut 2003;52:1638–1643PubMedPubMedCentralCrossRef
39.
Khalili M, Kleiner D, W. K, et al. Hepatic fat and steatohepatitis in a large multiethnic north American cohort of adults and children with chronic hepatitis B. Hepatology, City;2019:107A.
40.
Baroni GS, Pastorelli A, Manzin A et al. Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C. Liver 1999;19:212–219PubMedCrossRef
41.
Seto WK, Fung J, Cheung KS et al. Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. Aliment Pharmacol Ther 2016;44:1071–1079PubMedCrossRef
42.
Zheng RD, Xu CR, Jiang L, Dou AX, Zhou K, Lu LG. Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis. Int J Med Sci 2010;7:272–277PubMedPubMedCentralCrossRef
43.
44.
Choi HSJ, Brouwer WP, Zanjir WMR et al. Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B. Hepatology 2020;71:539–548PubMedCrossRef
45.
Chen YC, Jeng WJ, Hsu CW, Lin CY. Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study. BMC Gastroenterol 2020;20:146PubMedPubMedCentralCrossRef
46.
Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003;125:1695–1704PubMedCrossRef
47.
Petta S, Macaluso FS, Barcellona MR et al. Serum gamma-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. PLoS One 2012;7:e51165PubMedPubMedCentralCrossRef
48.
Petta S, Camma C, Di Marco V et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver Int 2011;31:507–515PubMedCrossRef
Metadata
Title
Advanced Liver Fibrosis Is Associated with Necroinflammatory Grade but Not Hepatic Steatosis in Chronic Hepatitis B Patients
Authors
Yi-Cheng Chen
Chao-Wei Hsu
Wen-Juei Jeng
Chun-Yen Lin
Publication date
01-12-2021
Publisher
Springer US
Keyword
Hepatitis B
Published in
Digestive Diseases and Sciences / Issue 12/2021
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06761-x

Other articles of this Issue 12/2021

Digestive Diseases and Sciences 12/2021 Go to the issue

Original Article

Hepamet Fibrosis Score in Nonalcoholic Fatty Liver Disease Patients in Mexico: Lower than Expected Positive Predictive Value

Review

Prevalence and Impact of Post-traumatic Stress Disorder in Gastrointestinal Conditions: A Systematic Review

Correspondence

Risk Factors for Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt: Beyond Stent Diameter

Correspondence

Transjugular Intrahepatic Portosystemic Shunt: A Single-Centre Mid-term Experience Using the Viatorr Controlled-Expansion Stent

Original Article

Low Levels of Fecal Calprotectin 3 Months After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohn’s Disease

Original Article

Lidocaine Inhibits Hepatocellular Carcinoma Development by Modulating circ_ITCH/miR-421/CPEB3 Axis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits